AR129441A1 - Péptidos y métodos para el tratamiento del dolor - Google Patents
Péptidos y métodos para el tratamiento del dolorInfo
- Publication number
- AR129441A1 AR129441A1 ARP230101325A ARP230101325A AR129441A1 AR 129441 A1 AR129441 A1 AR 129441A1 AR P230101325 A ARP230101325 A AR P230101325A AR P230101325 A ARP230101325 A AR P230101325A AR 129441 A1 AR129441 A1 AR 129441A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptide
- pain
- identity
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305773 | 2022-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129441A1 true AR129441A1 (es) | 2024-08-28 |
Family
ID=81975215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101325A AR129441A1 (es) | 2022-05-25 | 2023-05-24 | Péptidos y métodos para el tratamiento del dolor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250213654A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4531886A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025519127A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250017221A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119730868A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129441A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023275937A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253053A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL317048A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014419A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202409064A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023227731A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026119985A1 (en) * | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating wounds and inflammatory diseases |
| WO2026119983A1 (en) | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating pain, wounds and inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| WO2006013462A2 (en) * | 2004-07-30 | 2006-02-09 | Nsgene A/S | Growth factors nsg28, nsg30, and nsg32 |
| CN103382220A (zh) * | 2012-05-03 | 2013-11-06 | 北京大学 | 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用 |
| EP2801369A1 (en) | 2013-05-06 | 2014-11-12 | Centre National De La Recherche Scientifique | TAFA4 compounds and uses thereof for treating pain |
| CN108699604A (zh) | 2016-03-08 | 2018-10-23 | 艾克斯-马赛大学 | 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途 |
-
2023
- 2023-05-24 AR ARP230101325A patent/AR129441A1/es unknown
- 2023-05-25 US US18/868,199 patent/US20250213654A1/en active Pending
- 2023-05-25 KR KR1020247041847A patent/KR20250017221A/ko active Pending
- 2023-05-25 IL IL317048A patent/IL317048A/en unknown
- 2023-05-25 AU AU2023275937A patent/AU2023275937A1/en active Pending
- 2023-05-25 CN CN202380053577.6A patent/CN119730868A/zh active Pending
- 2023-05-25 CA CA3253053A patent/CA3253053A1/en active Pending
- 2023-05-25 JP JP2024569387A patent/JP2025519127A/ja active Pending
- 2023-05-25 EP EP23728752.9A patent/EP4531886A1/en active Pending
- 2023-05-25 WO PCT/EP2023/064091 patent/WO2023227731A1/en not_active Ceased
- 2023-05-25 TW TW112119546A patent/TW202409064A/zh unknown
-
2024
- 2024-11-21 MX MX2024014419A patent/MX2024014419A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024014419A (es) | 2024-12-06 |
| IL317048A (en) | 2025-01-01 |
| AU2023275937A1 (en) | 2024-12-12 |
| KR20250017221A (ko) | 2025-02-04 |
| CA3253053A1 (en) | 2023-11-30 |
| CN119730868A (zh) | 2025-03-28 |
| TW202409064A (zh) | 2024-03-01 |
| WO2023227731A1 (en) | 2023-11-30 |
| EP4531886A1 (en) | 2025-04-09 |
| JP2025519127A (ja) | 2025-06-24 |
| US20250213654A1 (en) | 2025-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230301A1 (es) | Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion | |
| AR123978A1 (es) | Variantes de la interleucina-18 y métodos de uso | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| PE20241187A1 (es) | Moleculas de arn | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| MX2022014082A (es) | Secuencias de interleucina (il-2) y usos de las mismas. | |
| AR125379A1 (es) | Un fab anti-tslp con estabilidad mejorada | |
| CU24746B1 (es) | Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular | |
| PE20231442A1 (es) | Proteinas actrii y sus usos | |
| DE69834136D1 (de) | Gefrierschutzprotein | |
| AR114722A1 (es) | Composiciones de erenumab y usos de las mismas | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| McGee et al. | Human seminal vesicle-specific antigen during semen liquefaction | |
| AR132053A1 (es) | Composiciones para su uso en el tratamiento de clamidia | |
| MX2021011407A (es) | Proteinas de dominio ccn recombinantes y proteinas de fusion. | |
| Brunati et al. | Isolation and identification of two proto‐oncogene products related to c‐fgr and fyn in a tyrosine‐protein‐kinase fraction of rat spleen | |
| JP2025519127A5 (cg-RX-API-DMAC7.html) | ||
| AR129864A1 (es) | Péptidos y métodos para uso en tratar el dolor | |
| Neurath et al. | The Denaturation of Proteins and its Apparent Reversal. III. | |
| MX2024008759A (es) | Peptidos y composicion farmaceutica para el tratamiento de tumores. | |
| DK1296675T3 (da) | Sammensætninger baseret på aminosyrer, egnet til behandling af hjertesvigt | |
| Liao et al. | Structural characterization of dioscorin, the major tuber protein of yams, by near infrared Raman spectroscopy | |
| WO2024016011A3 (en) | Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses | |
| Chijiwa et al. | Suppression of severe lesions, myonecrosis and hemorrhage, caused by Protobothrops flavoviridis venom with its serum proteins |